Noxopharm (ASX:NOX) - Chief Medical Officer, Gisela Mautner
Chief Medical Officer, Gisela Mautner
Source: Noxopharm
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’
  • Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board
  • Dr Mautner joined Noxopharm three years ago and oversaw the implementation of the company’s clinical programs
  • Dr Kelly will remain actively involved in Noxopharm’s future given his previous impact on the company
  • Noxopharm’s share price was up 4.9 percent to trade at 43 cents at midday AEDT

Noxopharm Limited (NOX) announces a shift in leadership in preparation for an upcoming ‘growth phase’.

Dr Gisela Mautner has been appointed as CEO starting next month, with former CEO Dr Graham Kelly remaining on the board, shifting from an executive to a consulting role.

Dr Mautner, currently the Chief Medical Officer, will earn $410,000pa and will also serve as Executive Managing Director on the board.

“I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next stages,” she said.

“I look forward to working with the board and the talented team at Noxopharm to deliver success and value for our many stakeholders.”

Dr Mautner is a medical doctor with pharmaceutical industry experience covering all aspects from clinical research to product commercialisation.

In her early career, Dr Mautner worked as a clinical scientist at the National Institutes of Health in the USA.

Dr Mautner has a master’s degree in public health from Harvard University and an MBA from Northwestern University, Kellogg School of Management and has served on the executive committee of the Australian Pharmaceutical Medical and Scientific Professionals Association (APPA).

Dr Mautner joined Noxopharm three years ago and oversaw the implementation of the company’s clinical programs.

Dr Kelly said the company is in the process of transiting from an early-stage biotech company into a serious bio-pharma company looking to make its mark on the world stage.

“As the company’s largest shareholder, ongoing board member and inventor of much of the company’s intellectual property, I intend to remain actively involved in the company’s future,” he said.

Noxopharm shares were in the green by 4.9 percent at 43 cents at midday AEDT.

NOX by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece